Core Points - Klotho Neurosciences has regained compliance with NASDAQ listing requirements, including a minimum bid price of $1.00 and stockholders' equity of at least $2.5 million [1][2] - The company is focused on developing gene and cell therapies for neurodegenerative and aging-related diseases, utilizing a patented form of the "anti-aging" human Klotho gene [4] - Klotho will be monitored for compliance with the stockholders' equity requirement for one year, with potential delisting if it falls out of compliance [3] Company Overview - Klotho Neurosciences specializes in innovative, disease-modifying therapies for conditions such as ALS, Alzheimer's, and Parkinson's disease [4] - The company's portfolio includes proprietary cell and gene therapy programs using DNA and RNA, as well as genomics-based diagnostic assays [4] - The management team consists of experienced individuals in biopharmaceutical product development and commercialization [4]